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DEVELOPMENT OF THE EUROPEAN
BIOTECHNOLOGY INDUSTRYt
JOHN ASHWORTH, PH.D."
INTRODUCTION
What I propose to do in this Article, is to present an European Union
perspective on the topic of governmental regulation of the biotechnology
industry. There were two fundamental developments in the 1970s that
launched the biotechnology industry in the 1980s. The first of these was the
development of genetic engineering into a practicable, routine procedure that
could be used outside the research laboratory; the second, of course, was
Georges K6hler' and Cesar Milstein's demonstration of monoclonal antibody
technology,2 for which they received the Nobel Prize.3 Both of these
t This Article is based on a report, and draws on data, submitted to the European
Parliament and the Directorate General for Research by Panos Kavanos, Elias Mossialos, and
Brian Abel-Smith of the London School of Economics. I am grateful for their permission to
quote from their research.
* Appointed Director of the London School of Economics and Political Science in October
of 1990 and Pro-Vice Chancellor for Metropolitan Affairs of the University of London 1991-92.
Previously, he held the posts of Vice-Chancellor of the University of Salford (1981-90) and
Chief Scientist of the Central Policy Review Staff in the Cabinet Office (1976-81) where he
advised Prime Ministers Callaghan and Thatcher.
Before that, he was foundation Professor of Biology at the University of Essex, has degrees
in chemistry and biochemistry and has published articles on biochemical, cell biological, genetic,
physiological, and educational topics. He has been an ex officio member of the Advisory Board
for the Research Councils, the Advisory Council for Applied Research and Development, UK
Titulaire on the Comite de Ia Recherche Scientifique et Technique (CREST) of the EEC, UK co-
chairman of the UK/USSR Joint Committee on Science and Technology, a member of the
Electronics Economic Development Committee of the National Economic Development Council,
the Council of the Economic and Social Research Council, and Chairman of the National
Accreditation Council for Certification Bodies (BSI), the Board of the National Computer Centre
and the Technical Advisory Committee, Jaguar Cars Limited.
He is currently a non-executive Director of Granada Group plc and J. Sainsbury plc, a
member of DEMOS Advisory Council, a governor of the Ditchley Foundation; and a Deputy
Chairman of London First.
1. Georges K6hler was born in West Germany in 1946. In the 1970s, he went to
Switzerland to study at the Institute for Immunology. In 1975, he went to Cambridge and
engaged in a collaborative effort which culminated in a celebrated paper in the scientific journal,
Nature. In late 1975, K~hler returned to Switzerland. He became a member of the European
Molecular Biology Organisation. In 1985, he became the director of the Max Plank Institute.
He died at the age of 48 in April of 1995. Obituary ofGeorges Kehler, THE DAILY TELEGRAPH
(London), Apr. 7, 1995, at 25.
2. Antibodies are the body's defence against disease and infection. When bacteria or viruses
invade-or cells become abnormal, as in the case of cancer-the B (bone marrow) lymphocyte cells
of the immune system recognize them as alien by reading the biochemical signatures on their
surfaces. The lymphocytes then produce complex protein molecules (antibodies which
specifically react with and neutralize the invaders). Living creatures can manufacture millions
of different antibodies, each fighting a particular type of foreign germ. Once a creature's
lymphocytes have produced an antibody, it is immune to that particular germ.
Doctors have known for years that antibodies are ideal for treating and diagnosing disease.
But the human body makes any one antibody only in minute quantities, and only when infected;
1
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developments were based on two decades of accelerating understanding and
research into molecular biology and genetics.
The traditional pharmaceutical industry was based on the chemical and
biochemical sciences. Although the industry was very well used to high
levels of research and development spending in the 1980s, it was slow to
realize the potential of these molecular biology developments. Thus, from its
inception, the biotechnology industry has been characterized by small, new
technology based firms (NTBFs in the jargon) started by scientists impatient
with the slow and ponderous behavior of the large pharmaceutical corpora-
tions. Now, in the 1990s, every pharmaceutical company wants access to
biotechnology. Since the late 1980s, a quieter revolution has been taking
place within the laboratories of the established pharmaceutical firms. The
procedures and some of the products of the NTBFs have been blended with
the traditional chemical and biochemical strengths of the older pharmaceutical
companies to produce a new kind of pharmaceutical entity: the
biopharmaceutical corporation.4
There have, however, been significant differences in the rate at which
these processes have occurred in different countries and there are now very
clear differences in the comparative advantage perceived by the three
dominant industrial players in our global economy: the United States, the
European Union, and, of course, Japan. This Article evaluates the competi-
and techniques for creating antibodies in animals never produced pure vaccines or reliable
diagnostic tests. K6hler found his work with lymphocytes difficult because they cannot be
maintained in a laboratory culture for more than a few days. In 1973 he attended a lecture given
by Cesar Milstein, a senior scientist at the Cambridge Molecular Biology Laboratory, who was
studying the abnormal way in which cancer cells produce antibodies. Cancer cells multiply out
of control, and can be used to make laboratory cultures that are "immortal." From his conversa-
tions with Milstein, K6hler realized that there might be a way of mass-producing any required
antibody outside the human body in a pure form, and so immortalizing its production.
To make an antibody to human cancer cells-to diagnose cancer and direct drug
intake-cancer cells are first injected into a mouse. The mouse begins making antibodies, which
are taken out of the mouse and fused with a strong-growing cell culture in the laboratory. This
hybrid culture, the hybridoma, will manufacture the antibody indefinitely and in any amount.
Antibodies made in this way are called monoclonal because they are made from a single cell line.
Monoclonal antibodies have had a huge impact in diagnostics, allowing precision and purity
in tests. They are now being evolved for use in therapy, and are already used in transplantation
for immuno-suppression, where they allow the production of crucial vaccines.
Id.
3. Georges K6hler, Cesar Milstein, and Niels Jeme received the Nobel Prize for Physiology
and Medicine in 1984, nine years after their paper on monoclanal antibodies was first published.
Id.
4. Biotechnology companies and established pharmaceutical companies are increasingly
pursuing the commercial development of biotechnology through joint efforts. The biopharma-
ceutieal corporation is forged usually through acquisition or merger, to enable the two entities
to pool their strengths and compete in concert. The biotechnlogy companies' strengths include
innovative research and technological capabilities which, when combined with monetary,
regulatory, and marketing strengths of established pharmaceutical companies, translate into new
pharmaceutical products. U.S. CONGREss, OFFICE oFTECHNOLOGY ASsEssMENT, BIOTECHNOLO-
GY IN GLOBAL INDUSTRY 94.
[Vol. 33
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tive position of the European Union in the evolving biopharmaceutical and
biotechnological areas. By analyzing the nature and extent of the United
States and, to a lesser extent, the Japanese presence in Europe, we may
hopefully put that competitive position into perspective.
BACKGROUND OF THE EUROPEAN BIOPHARMACEUTnCAL INDUSTRY
The European Union has maintained its position as a leading producer of
pharmaceuticals. The fifteen member states of the European Union5
accounted for 32% of world production in 1993, just ahead of the United
States at 31%, and Japan at 18%. Within the European Union, the German
industry is the largest national producer, supplying approximately one quarter
of the total European Union output. The next largest national producers are
the United Kingdom, Italy, and France, with about 15% to 20% each.
Interestingly, Spain is the fastest developing producer. What I just summa-
rized may be seen in Figure 16
5. The fifteen member countries of the European Union are as follows: Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands,
Portugal, Spain, Sweden, and the United Kingdom.
6. The sources used to compile this table are as follows: European Federation of
Pharmaceutical Industries' Association (EFPIA), Pharmaceutical Research and Manufacturers
Association of America (PhRMA), Japan Pharmaceutical Manufacturer's Association (JPMA).
3
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FIGURE 1
Basic Indicators of the European, US and Japanese
Pharmaceutical Industries
Production Consumption Employment R & D(1993) (1993)* (1993) (1992)
in ECUm in ECUm (employees) in ECUm
EU-12 61,358 46,631 451,138 7,789
Germany 15,941 13,057 122,485 2,268
U.K. 12,186 4,888 80,400 1,961
France 16,290 11,508 100,000 1,606
Italy 10,143 8,430 68,600 1,024
Spain 4,877 4,069 38,800 266
U.S.A. $84,900 na 353,743 $12,500
Japan Y5,574,000 na 150,452"" Y666,000
"Total consumption (including ambulatory, hospitals, OTC), at
ex-factory prices.
"*JPMA Member companies only.
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As well as being the largest pharmaceutical producer, the European
Union also represents one of the largest potential markets in the world, with
approximately 46 billion ECu 7 in 1993.' Thus, the European Union
represents the largest potential market with about 46 billion ECU, or 30.8%,
of the world market. The United States comprises 29%, and Japan comprises
19%. However, this is a somewhat misleading way of presenting this data,
for the fifteen member states of the European Union have still largely retained
their separate and different practices and priorities. Major internal barriers
to trade and harmonization of regulatory practices still exist.' Harmonization
of regulatory practices, although occurring, is proceeding quite slowly."0
The single market in pharmaceuticals in the European Union is still but an
aspiration rather than a reality.
There are a number of very serious consequences, as I shall go on to
illustrate, for the structure of the developing biopharmaceutical industry in
Europe. But first, I would like to finish this brief background summary by
pointing out that although large and growing, the pharmaceutical industry
only accounts for 0.62% of total European Union industrial production and
contributes a mere 0.78% to the European Union's gross domestic product
(GDP). Thus, although it is a very important industry to us, and although it
is clearly developing into a major force, it is still not yet large enough to
attract the attention of European politicians.
CONSEQUENCES OF THE STRUCTURE OF THE EUROPEAN
BIOPHARMACEUTICAL INDUSTRY
Disturbingly, the cash employment positions noted in Figure 1 clearly
illustrate that the productivity of the European Union industry in terms of
sales per employee is approximately 50% of the United States figure and 45%
of the Japanese figure. In absolute terms, the number of qualified scientists
and engineers employed in the United States and the European Union is very
similar. The over-staffing in the European Union is concentrated in those
functions such as sales and marketing and regulatory affairs, which are
needed to cope with the fifteen different markets and their different medical
7. ECU (European Currency Unit) is pronounced "e-que," with a French accent, and is
currently equal to one dollar and twenty-six cents. For an overview of the ECU, see ECONOMIC
AND MONETARY INTEGRATION EUROPEAN UPDATE, 1991 WL 11671 (D.R.T.) (last update May
20, 1996); Currency Trading, WALL ST. J., Nov. 1, 1996, at C16.
8. G. Steven Burrill, The European Biotech Industry: Gathering Momentum, BIOPHARM,
May 1995, at 12, available in WL, Magazine file.
9. BIOTECHNOLOGY IN A GLOBAL ECONOMY 21, 122-24 (Brown, Bart, ed., Oct. 1991).
10. Harmonization is a process in which various nations' patent, intellectual property, and
biotechnology regulations and practices are structured uniformally to enable consistent application
throughout the global industry. For instance, procedural distinctions between the laws of various
nations are receiving increased attention in forums convened to harmonize international patent
law. U.S. CONGRESS, BIOTECHNOLOGY IN A GLOBAL INDUSTRY, OFFICE OF TECHNOLOGY
ASSESSMENT 18-24 (1991).
5
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practices, ethics, health care systems and policies. Therefore, the efficiency
costs of not having a true internal market in the European Union is high and
the purpose of the London School of Economics (LSE) report, from which
this talk is drawn, was in part to highlight and substantiate these costs.
Given this situation, it is not surprising that the United States industry
also appears to be more research orientated, devoting 23.4% of its work force
to research and development, compared to the European Union's 13.4%.
Although expenditures on research and development have grown in the
European Union by an annual 15% over the last decade, and was estimated
to have exceeded 8 billion ECU in 1993, both as a percentage of sales and
in absolute terms, there is a growing gap between the United States and the
European Union.
The general picture, therefore, is of an historically important industrial
sector in the European Union tliat is slowly being overtaken. It is unable to
draw the strength it should from its internal market and is weakest in the
fastest growing sectors. This shows up most clearly in the trade figures, If
one defines an index, which for the economists amongst you is usually known
as the Balassa index," then the European Union has shown a decline from
0.39 in 1981 to 0.16 in 1990. That is a very serious decline. By comparison,
the United States had a value of 0.27 in 1989-just another way of expressing
the fact that the European Union industry as a whole is declining in the
fastest growing sectors.
Let me now turn from the pharmaceutical industry in general to the
impact of biotechnology and in particular, that of the developing biopharmac-
eutical industry in Europe. Today, biotechnology permeates both large and
small companies within the pharmaceutical industry. The LSE survey of
eight large multinational corporations in Europe shows that approximately
one-third of their research and development projects were in biotechnology.
Yet Figure 2 shows that the rate of growth has really been very slight.
11. The ratio of the sum of exports, plus imports, over the difference of exports, minus
imports:
Exports + Imports
= Index
Exports - Imports
[Vol. 33
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FIGURE 2
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Within the European Union, research and development expenditures on
biotechnology projects are concentrated in the United Kingdom, Germany,
and France. A closer examination of these three countries, however, shows
marked differences in their comparative competitive positions. These can be
summarized in terms of six key parameters:
1. a pre-existing pharmaceutical industry;
2. the amount and type of government support;
3. relationships between universities and industrial sponsors;
4. availability of private venture capital;
5. the legal framework for environmental protection and safety at
work and patenting; and
6. research and development expenditures and policies.
I want to mention each of these six areas briefly in the European Union
context, but my conclusion probably will not surprise you. In the biotechnol-
ogy industry, as in many others, the United Kingdom's situation looks much
more like the United States' than do the French or German situations, with
all the strengths and weaknesses of the Anglo-Saxon capitalist structure
compared with the Continental European, or Rhenish, model.'"
In terms of the pre-existing industrial base, Germany, the largest single
European Union biopharmaceutical producer, has historically possessed
considerable assets in terms of its chemical expertise. Ironically, these assets
have inhibited the rapid development of biotechnology within German
chemically-based pharmaceutical companies. 3 The situation in France
appears to be similar. Furthermore, there has been no development of a small
NTBF biotechnology sector in those countries to compensate for the caution
of the large, traditional, chemically-based pharmaceutical companies. Only
in the United Kingdom does one see a significant number of the small,
entrepreneurial firms such as CellTech, ChiroScience, and British Biotechnol-
ogy based on university spinoffs, which is such a feature of the United States
industry. You do not see companies such as these in France or Germany.
Governmental support and initiatives, shown in Figure 3, have reinforced
this trend in the United Kingdom. Europeans envy the way in which the
United States government funds new biotechnology developments through at
12. Unlike the Anglo-Saxon capitalist structure in the United States and the United
Kingdom, which is an economically liberal free-market model, the Continent Capitalist structure
is more illiberal, with labor and capital operating within allotted roles. For further information
regarding the differences between the Anglo-Saxon and Continental capitalism models, see The
End of Never-Never-Land, TBE ECONOMIST, Feb. 13, 1993, at 17; James Ball, The European
Union: The Road to Nowhere, 8 EUR. BUS. J. 31 (1996).
13. The strength of Germany's traditional chemically-based pharmaceutical companies has
placed them in a comfortable niche. Thus, these pharmaceutical companies seem hesitant to
compromise their positions by venturing forth into the more experimental biotechnology market.
[Vol. 33
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least six major competing departments: National Institute of Health (NIH), 4
National Science Foundation (NSF),"5 the Department of Energy, 6 the
Department of Agriculture, 7 the Environmental Protection Agency," and
14. The NIH is a federal agency that underwrites research in its own laboratories, as well
as in those at private and public institutions by awarding grants and contracts.
In the area of biotechnology, NIH-supported research can be divided in two
categories. The first is basic research directly related to biotechnology, which
includes recombinant DNA techniques; gene mapping and DNA sequencing; isolation,
separation, and detection of DNA; the creation of hybridomas; the production of
monoclonal antibodies; protein engineering; production of antibody-tom chimeras
(immunotoxins); and the computer analysis of DNA and protein sequences. The
second category relates to the broad research underlying biotechnology and refers to
studies in the fields of genetics, cellular and molecular biology, biological chemistry,
biophysics, immunology, virology, macromolecular structure and pharmacology. For
the basic research studies directly related to biotechnology, NIH provided an estimated
$1.19 billion in fiscal year 1990. For the broadly based research area, NIH provided
and estimated $1.7 billion in fiscal year 1990. Thus, for fiscal year 1990, NIH
provided an estimated $2.9 billion for biotechnological research through its research
grants and contracts mechanisms for its intramural component.
U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, BIOTECHNOLOGY IN A GLOBAL
ECONOMY 249 (1991).
15. The NSF is a federal agency that supports basic research in the United States' colleges
and universities. In fiscal year 1990, the NSF budget comprised about 7% of the federal
nondefense budget for research and development. About 94% of the NSF budget is used to
support basic research; about 6% of the NSF budget supports applied research.
NSF specifies a category of work as related to biotechnology if it includes research
activities related to the following: environmental applications; bioprocessing and
bioconservation; bimolecular materials; bioelectronics and bionetworks; agricultural
applications; medical applications; and impact of biotechnology.
NSF's total support for biotechnology-related research in fiscal year 1990 was
$167.9 million.
Id. at 251-52.
16. The Department of Energy (DOE) funds biotechnology research through three main
programs: Basic Energy Sciences, Biological and Environmental Research (both of which are
part of the Office of Energy Research), and Conservation and Renewable Energy.
The Basic Energy Sciences program, which focuses on the transformation of biomass into
other forms, was funded at approximately $20.4 million in fiscal year 1990. Id.
The Biological and Environmental Research program, which focuses primarily on human
genome and structural biology programs, was funded at $54.9 million in fiscal year 1990.
The Conservation and Renewable Energy program focuses on bioprocessing industrial and
municipal wastes into fuels, and was funded at $6.9 million in fiscal year 1990.
17. The Department of Agriculture (USDA) funds biotechnology research and development
through four different agencies: the Agricultural Research Service (ARS), the Cooperative State
Research Service (CSRS), the Forest Service, and the Economic Research Service (ERS).
The ARS is the USDA's main research agency. ARS funds processes in order to solve
agricultural problems. In fiscal year 1990, ARS received approximately $59.2 million in funding.
The CSRS is the USDA's liaison to the state university system. The CSRS handles diverse
funding to university research projects, and was fumded at about $52.2 million in fiscal year
1990.
The Forest Service funds biotechnology research to improve the cultivation of trees and
plants by improving their growth and resistance to disease. The Forest Service also funds the
testing and development of new industrial processes for wood. In fiscal year 1990, the Forest
9
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the Food and Drug Administration. 9 This funding stimulates and supports
a highly competitive industrial and regulatory structure. The European Union
picture is much smaller and much more bureaucratic.
FIGURE 3
Public Funding of Biotechnology in selected
countries
Service was funded at approximately $3.6 million.
ERS analyzes developments in agricultural technology and studies their potential foreign
and domestic economic impacts. Research in the area of biotechnology includes forecasting the
economic conditions under which animal growth hormones should be utilized and risk-
management in biotechnology. ERS expended roughly $250,000 on economic analysis of
biotechnology in fiscal year 1990. Id. at 253-54.
18. Although largely a regulatory agency, the Environmental Protection Agency (EPA) has
a significant budget for research and development to produce a scientific basis for its regulations.
EPA focuses on biotechnology risk assessment, particularly the impact of genetically-altered
microorganism on humans and the environment. EPS' total biotechnology funding in fiscal year
1990 was $8.3 million. Id. at 255.
19. The Food and Drug Administration (FDA), which is responsible for the safety of foods,
cosmetics, drugs, biologics, medical devices, and radiological products, monitors and evaluates
the industry to assure products which are produced are safe and effective. Biotechnology has had
a major impact on the development of products that the FDA regulates. The agency's focus is
to maintain a research expertise in the field in order to have the knowledge necessary to approve
new pharmaceuticals and other items regulated by the FDA in a minimum of time. The FDA
spent approximately $19.4 million on biotechnology research in fiscal year 1990. Id. at 256.
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Community research and development money is largely channeled
through Bimolecular Engineering Programme and Biotechnology Action
Programme, which are funded at nowhere near the extent of their United
States equivalents." This competitive use of public money is paralleled by
its flourishing venture capital market in the United States, which is unknown
in Continental Europe, and exists only to a much more minor extent in the
United Kingdom.
The consequence is that in much of the European Union, large multina-
tional corporations such as Bayer, Roche, and Glaxo, either set up laborato-
ries in the United States2 or compensate for the shortcomings in the
European Union situation by buying into United States research, develop-
ments, and firms. I do not totally accept the notion that this implies that the
United States taxpayer is giving something away for free, because it seems
to me that the European Union firms have paid top-dollar for some of their
investments. However, I leave that perhaps to discussion.
Martine Kraus addresses the legal situation of this area in more detail in
her article.2 Let me just briefly mention that the European Union regula-
tions were only adopted at the Community level in March 1990 for the
contained use and deliberate release of genetically engineered organisms. The
regulatory situation is still uncertain and there is considerable room for legal
conflicts and different interpretations.
Public opinion has had an important impact in this area, as has been
sadly illustrated by the current "mad-cow disease" crisis in Europe.23 Public
20. The Biotechnology Action Programme (BAP) is a community organization which,
among other things, supports biotechnology research and development and coordinates efforts for
harmonization. BAP was established in 1985 and funded at $50 million. Mark Dibner,
Biotechnology in Europe, SCIENCE, June 13, 1986, at 1367.
21. All of these companies have laboratories in the United States.
22. See generally, Martine Kraus, Ph.D., A Comparison of Drug Approval at the FDA and
the EMEA/CPMP, 33 CAL. W. L. REV. 101 (1996) (this volume).
23. Bovine spongiform encephalopathy, more commonly known as "mad-cow" disease, is
a brain disease which affects beef and dairy cattle. Mad-cow disease was first identified in 1986.
The foremost theory for the origin of mad-cow is that it came from scrapie, a fatal viral disease
found in sheep. (Scrpie is characterized by twitching, excitability, excessive thirst, weakness,
and, in its latter stages, paralysis).
Britain, which has a $7.5 billion-per-year beef industry, is the only European country in
which mad-cow disease exists. This is typically explained by citing the presence of a number
of factors, including a high infection rate of sheep with scrapie and the practice of grinding and
then feeding to cows sheep brains as a protein supplement.
In November 1995, some scientists theorized that there is a close link between mad-cow
disease and Creutzfeldt-Jakob Disease (CJD), a rare but fatal human brain disease that had
recently claimed the lives of ten Britons. The theory was expanded to hypothesize that the
human disease could be traced to an abnormal protein in the cell membrane which, if consumed,
could be transferred and damage proteins in the host. Although the Ministry of Agriculture,
Fisheries and Food produced a number of scientists who showed that it was unlikely for the
disease to be transmitted across species, other scientists disagreed. Debates regarding this link
were common in British medical journals.
Although no conclusive link could be proved or disproved, public opinion regarding the
matter was clear. In January 1996, Nielsen statistics showed that 1.4 million households had
ceased to buy British beef. From November to mid-December, beef sales declined by 25% from
the similar period in 1994. The most notable decline occurred in hamburger sales, which fell by
11
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opinion has led to a general over-concentration in the biotechnology sector
on the regulation of genetic engineering processes. This differs from the
United States, which concentrates on the nature of the products produced.24
The European concentration has slowed the construction of a secure
regulatory environment and led to great conflicts in the one we have already
partially constructed."
In the area of intellectual property rights, the issue seems to have been
solved, at least at the European Union level, with the adoption of a European
Council regulation in April 199426; however, the biotechnology industry has
expressed serious concerns regarding the practicality of the interpretation and
form of that regulation.27 Quite simply, this means that we will be mired
in the European courts for a long time, trying to decide exactly what that
European Council regulation means.
Europeans believe that the United States grants patents with much
broader scope and claims than would be allowed in the European Union and
at the national level. Of course, the standards and intellectual property rights
regimes vary amongst the members of the European Union and, often in a
confusing and bewildering way, between the European Patent Office in
Munich and the various national legal authorities. This muddle is being
sorted out, but it is taking far too much time in the view of industrialists who
40%. John Darnton, Fear of Mad-Cow Disease Spoils Britain's Appetite, N.Y. TIMES, Jan. 12,
1996, at Al.
Then, in March 1996, Health Secretary Stephen Dorrell reported to the House of Commons
that the most likely explanation for the recent outbreak of CJD was exposure to mad-cow disease.
Nearly every country in the European Union, as well as other countries around the world,
imposed bans on the importing of British beef. But the worst blow came on March 27, 1996,
when the European Commission imposed a world-wide ban on the exporting of British beef and
a variety of products containing beef byproducts. John Darnton, Europe Orders Ban on Exports
of British Beef, N.Y. TIMEs, Mar. 28, 1996, at Al.
Almost three months later, on June 22, 1996, the European Commission agreed to a plan
that would gradually repeal the ban on British beef. The plan, however, contains no specific
dates for an end to the ban, and requires Britain to destroy approximately 120,000 cattle. John
Darmton, For the British Beef War: A Truce but No Victory, N.Y. TIMES, June 24, 1996, at A9.
The impact of the mad-cow scare on the British economy was severe. The Office for
National Statistics reported that the decline in beef sales resulting from the mad-cow scare
reduced Britain's quarterly GDP growth by a tenth of a percentage point for the second quarter
of 1996. Although forecasted to do so to a lesser extent, the mad-cow scare is also likely to
impact Britain's third quarter GDP figures as well. Farm Woes Curb British Growth, N.Y.
TIMES, July 27, 1996, § 1, at 40.
24. See Michael J. Malinowski, A False Start? The Impact to Federal Policy on the
Genotechnology Industry, 13 YALE J. ON REG. 163 passim (1996).
25. Thomas C. Vinje, Recent Developments in European Intellectual Property Law: How
Will They Affect You and When? 13 J.L. & COM. 301, 313 (1994); Richard Evans, The Banking
and Currency Power, Technology and the Future of the Market Economy, 12 SANTA CLARA
CoMPUTER & HIGH TECH. L.J. 381, 401-01 (1996); Victor Vadebeck, Realizing the European
Community Market by Unifying Intellectual Property Law: Deadline 1992, 1990 B.YU.L. REV.
1605 passim (1992).
26. Council Decision 110/94, 1994 O.J. (L126).
27. R.R., Sun Could Set on British Biotech Unless Regulations Lighten Up, BIOTECHNOLOGY
NEWSWATCH, Oct. 18, 1993, at 1; Harold C. Wegner, Impact of the TRIPs Agreement on Specific
Discipline Patentable Invention, 29 VAND. J. TRANSNAT'L L. 535 (1996).
[Vol. 33
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are only too aware of the speed with which the technology and underlying
science is developing.28
UNIVERSITY AND INDUSTRY RELATIONS
Finally, I wish to mention university-industry relations. It is important
to remember that, aside from the United States, only the United Kingdom
regards universities as legally autonomous institutions. In most of Europe,
universities are part of the state, and university faculty are therefore civil
servants.29 As civil servants, the university faculty were forbidden, at least
until very recently, to accept consultancy payments or enter into exclusive
deals with commercial interests. This, together with the lack of a mature
venture capital market, largely accounts for the absence of flourishing small
biotechnology firms.
In Britain, it was largely cultural, rather than legal, difficulties that
inhibited entrepreneurial academic commercial activity. To an American eye,
the United Kingdom universities would probably appear in these terms to be
behaving much as the United States did fifteen or twenty years ago.3"
Within the United Kingdom, as well as in the European Union more
generally, both the legal and cultural frameworks are quickly changing."
We all recognize that in a knowledge-driven industrial world, there is no
place for the academic ivory towers of old.
28. To what extent have the uncertain intellectual property rights regimes limited
investment? The simple answer is that it must have inhibited it a lot. It is one of those factors
which, for example, led ChiroScience, one of our more successful small companies, to trade on
the New York Stock Exchange rather than in the city of London. The uncertainty has meant that
in this sector, the United Kingdom has tried to be a colony of America, rather than a free entity
in its own right.
29. In France, for example, not only are they civil servants, but the elite of them, who work
not in the universities but in the Grand Zecal, are issued with uniforms and swords on formal
occasions.
30. It is a useful rule of thumb that says that whatever America is doing now, we in the
United Kingdom will do in fifteen or twenty years' time. It seems that in this area, that rule of
thumb holds.
31. The United Kingdom scientists are becoming entrepreneurs. They are no longer
confined by government. British universities are legally autonomous and, starting with Mrs.
Thatcher's administration in 1980, the government funding for universities has been decreasing.
In the 1980s, between 80% and 90% of a typical university's income, (excepting Oxford and
Cambridge) came directly from the government. Now the figure is between 30% and 50%.
The pressure of these budget cuts has led the academics to routinely predict the end of
civilization as they know it and go out and raise more money. Although this has generated an
enormous amount of whining and complaining, it has led the legal powers which were always
there to set up companies and engage in the kind of activities which I can remember seeing with
so much amazement when I was in the United States 30 years ago. That is now being
redeveloped. The French and the Germans are looking with equal interest at what the United
Kingdom and the United States are doing. They are also changing their legal status as well. It
is now possible for German academics to engage in consultancy, to sign exclusive consultantships
with companies, and so on and so forth. I think given five or ten years, you will see much more
of what we still regard as typically U.S. behavior.
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Given this recital of ancient strengths and gradually appearing contem-
porary weaknesses, how are the European Union firms likely to respond? It
is clear that they will seek to compensate for the rigidities and fragmented
market structures within the European Union, which is fated to last for at
least the next five to ten years. The firms will compensate first by directing
an increasing fraction of their investments to the United States.
Figure 4 compares what was happening in 1980 with what was happening
in 1988. The trends shown here have been accelerating since 1988.
14
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FIGURE 4
Stocks of Inter-regional Direct Investment in Pharmaceuticals
32
in millions of U.S. dollars
Origin Destination
United Western Rest of
States Europe Japan World Total
End 1980
United States 5,080 604 3,366 9,050
Western Europe 2,558 - 268 na 2,826
Japan 9 4 - 47 60
Rest of World 377 na na - 377
Total 2,944 5,084 872 3,413 12,313
End 1988
United States - 13,830 3,047 3,366 22,087
Western Europe 10,818 - 2,660 na 13,487
Japan 436 150 - 47 993
Rest of World 829 na na - 829
Total 12,083 13,980 5,707 3,413 37,387
32. Source: Secretary for Trade Industry (ST1) review, Organization for Economic
Cooperation and Development (OECD), 1993.
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Look first of all at where investment capital was coming from, which is
the origin, and then look at where it went. You can see that in 1980, the
United States invested some 5 million U.S. dollars in Western Europe,
whereas it invested nearly $14 million in 1988, an increase of nearly three-
fold. But compare that with the increase of Western European investments
in the United States from just over $2 billion in 1980, to nearly $11 billion
in 1988, a five-fold increase. Although we are all investing in each others'
markets, the Western Europeans are investing faster in the United States than
the United States is reciprocating by investing in Western Europe.3 This
is a marked pattern, and one that I expect will continue. It is also interesting
that although starting from a very small base, all of us are beginning to invest
quite heavily in Japan.
As the European Union firms invest in the United States, the United
States firms will seek to buy market shares in the European Union.
Remember, the European Union is still the largest market. When the internal
barriers are finally removed, it will be an extremely attractive market to be
in, and the United States companies realize this34 ; but note that the motiva-
tion for their investment is rather different. European Union firms are
investing to gain knowledge, investing in research and development,
purchasing, merging, acquiring, or having strategic allegiances with some of
33. The lack of venture capital in Europe may be attributed to varying situations amongst
the different countries. In Germany, for example, the banks have traditionally played the role
which, in America, venture capitalists play. Banks such as the Deutsche Bank routinely have
large stocks of shares in companies they support. Furthermore, the industrial structure is much
more akin to that of the Japanese, which has a bank that owns the stock of a cluster of companies
around it. And in France, the state has traditionally played, since the days of Colbert, the role
of industrial sponsor.
In the United Kingdom, we have a situation much more akin to that in America, except that
the United Kingdom is a much smaller economy; one must remember that, in economic terms,
the whole of the United Kingdom is smaller than California. Although there is a venture capital
sector, it has never grown at quite the same rate as the American sector. One of the reasons for
this is that for a venture capitalist in the city of London, it always seems more attractive to put
your money in America than it does in the United Kingdom. This is simply because the market
sizes are so different. The clever men who draw the economic analyses will always tell one to
invest in the United States.
34. In response to Commissioner Lehman's forecast of a trade war, Bruce Lehman, Major
Biotechnology Issues for the U.S. Patent and Trademark Office, 33 CAL. W. L. REv. 49, 60-61(1996) (this volume), I instead foresee robust negotiations between the European Union the
United States. Ultimately, it will be in everybody's interest to come to a mutually satisfactory
outcome because we have a shared interest in having a successful industry. Furthermore, if you
believe in the theories of globalization, then that industry must be worldwide; it cannot be
restricted to one geographical area. However, I do not want to challenge the Commissioner's
predictions entirely. The Commissioner was absolutely right when he noted the deep-seated
philosophical differences which have understandable legal and historical bases such as the
European Patent Office's and the United States' differing approaches to the problems of patenting
mice. Although I do not believe there will be a major trade war, there will be a tremendous row
from time to time.
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those small biotechnology companies." In fact, Chiron has a number of
such relationships. This is the cash equivalent of those deals in Figure 4.
The motivation for the United States firms is quite different. They are
buying into a market. They already have the research and development, and
they already have the knowledge. They are buying into a market and buying
a market share. This increase in mutual reciprocal investment is but a
specific example of the globalization we hear so much of from the manage-
ment gurus. Not surprisingly, one can see it in a very clear and unambiguous
form here, because this is a technology-driven, high-technology industry.
This is where the cutting edge of globalization is most clear.
An important part of European Union investments in the United States
is alliance, merger, or acquisition activity between large European Union
pharmaceutical corporations and small United States biotechnology compa-
nies. I am sure we will see much more of that in the future, together with a
developing European Union sector of small biotechnology start-up companies
paralleling the American experience about fifteen or twenty years later.
British BioTech shares, for example, have gone from £4 to £30 in the past 18
months. This has attracted a lot of attention, not only from American venture
capitalists, but also from the growing number of European capitalists as well.
I am sure that one or two successes like British Biotech will be followed up
by European Union investors.
CONCLUSION
The one policy conclusion for the European Union from all of this is
clear: In this industrial sector above all, the European Union really must
create the Single Market that was the dream of those who signed the Treaty
of Rome36 all those years ago and which still has evaded their successes, at
least in this area of industrial activity.
35. An example of this may be found in Dr. Edward Penhoet's Article. Edward Penhoet,
Ph.D., Science & Technology Policy: A CEO's View, 33 CAL. W. L. REV. 15, 20 (1996) (this
volume).
36. Treaty Establishing the European Community, Mar. 25, 1957, 298 U.N.T.S. 167.
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